{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:31:59Z","timestamp":1790310719456,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4\/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer. In efforts to mitigate neutropenic toxicities, oncologists in real-world practice have prescribed alternative dosing strategies with palbociclib, yet the implication on PFS is unknown. Methods: We conducted a retrospective, observational chart review of all female patients at our clinics with HR+, HER2- metastatic breast cancer receiving palbociclib in combination with either letrozole or fulvestrant with a first dose initiated between June 2016 and December 2018 and followed their disease course until 30 April 2020. Results: The median PFS for all clinic patients receiving palbociclib and letrozole (n = 63) was 40.8 months (95% confidence interval (CI) 25.6\u2013not estimable) and 16.97 months (95% CI 8.57\u2013not estimable) for patients receiving palbociclib and fulvestrant (n = 11). We identified seven alternative dosing strategies prescribed by oncologists, the most prevalent being prescribing palbociclib for three weeks on and two weeks off (n = 8). The Kaplan\u2013Meier curves for PFS in patients receiving letrozole and palbociclib prescribed alternative dosing strategies appear to diverge from monograph dosing early in the treatment. Many patients prescribed palbociclib using alternative dosing strategies continued to be observed even by the 18-month timepoint. The prevalence of grade 4 neutropenia was lower for patients on palbociclib with letrozole, suggesting a possible mitigation of severe neutropenia with alternative dosing strategies. Conclusions: We conclude that alternative dosing strategies used by oncologists such as prescribing palbociclib for three weeks on, two weeks off may achieve comparable disease control while mitigating neutropenic toxicities when compared to standard monograph dosing recommendations, prolonging treatment tolerability and adherence. Further large-scale studies are needed to confirm these results for future clinical adoption.<\/jats:p>","DOI":"10.3390\/curroncol29030145","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:21:16Z","timestamp":1646648476000},"page":"1761-1772","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer"],"prefix":"10.3390","volume":"29","author":[{"given":"Fulbert","family":"Fu","sequence":"first","affiliation":[{"name":"Trillium Health Partners, Mississauga, ON L5M 2N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kano","sequence":"additional","affiliation":[{"name":"Trillium Health Partners, Mississauga, ON L5M 2N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute for Better Health, Trillium Health Partners, Mississauga, ON L5M 2N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mera","family":"Guindy","sequence":"additional","affiliation":[{"name":"Trillium Health Partners, Mississauga, ON L5M 2N1, Canada"},{"name":"Mohawk Medbuy Corporation, Burlington, ON L7L 0A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","article-title":"Global Cancer in Women: Burden and Trends","volume":"26","author":"Torre","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast Cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular Portraits of Human Breast Tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications","volume":"98","author":"Perou","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Howlader, N., Altekruse, S.F., Li, C.I., Chen, V.W., Clarke, C.A., Ries, L.A.G., and Cronin, K.A. (2014). US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI J. Natl. Cancer Inst., 106.","DOI":"10.1093\/jnci\/dju055"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ctrv.2017.09.003","article-title":"CDK4\/6 Inhibition in Early and Metastatic Breast Cancer: A Review","volume":"60","author":"Kuijpers","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating Cancer with Selective CDK4\/6 Inhibitors","volume":"13","author":"Finn","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN Guidelines Insights: Breast Cancer, Version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","article-title":"NCCN Guidelines Updates: Breast Cancer","volume":"16","author":"Giordano","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4\/6 Inhibitors: A Systematic Review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf."},{"key":"ref_15","unstructured":"(2022, February 14). Pfizer Canada ULC Ibrance Product Monograph. Available online: https:\/\/www.pfizer.ca\/sites\/default\/files\/202107\/Ibrance_PM_EN_243405_15-Jul-2021.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mycock, K., Zhan, L., Taylor-Stokes, G., Milligan, G., and Mitra, D. (2021). Real-World Palbociclib Use in HR+\/HER2- Advanced Breast Cancer in Canada: The IRIS Study. Curr. Oncol. Tor. Ont, 28.","DOI":"10.3390\/curroncol28010066"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Amaro, C.P., Batra, A., and Lupichuk, S. (2021). First-Line Treatment with a Cyclin-Dependent Kinase 4\/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta. Curr. Oncol., 28.","DOI":"10.3390\/curroncol28030209"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bui, T.B.V., Burgers, D.M., Agterof, M.J., and van de Garde, E.M. (2019). Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients with Advanced\/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy. Breast Cancer Basic Clin. Res., 13.","DOI":"10.1177\/1178223418823238"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clbc.2019.06.010","article-title":"Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer","volume":"20","author":"Wilkie","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2018.10.009","article-title":"Treatment Patterns and Clinical Outcomes among Patients Receiving Palbociclib in Combination with an Aromatase Inhibitor or Fulvestrant for HR+\/HER2-Negative Advanced\/Metastatic Breast Cancer in Real-World Settings in the US: Results from the IRIS Study","volume":"43","author":"Mitra","year":"2019","journal-title":"Breast Edinb. Scotl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","article-title":"Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy","volume":"176","author":"Varella","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/j.clbc.2018.09.002","article-title":"Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive\/HER2-Negative Metastatic Breast Cancer","volume":"19","author":"Watson","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4143\/crt.2020.451","article-title":"Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions","volume":"53","author":"Lee","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2217\/fon-2020-1264","article-title":"CDK4\/6 Inhibitors in HR+\/HER2- Advanced\/Metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies","volume":"17","author":"Harbeck","year":"2021","journal-title":"Future Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative Effectiveness of First-Line Palbociclib plus Letrozole versus Letrozole Alone for HR+\/HER2- Metastatic Breast Cancer in US Real-World Clinical Practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_27","first-page":"26","article-title":"Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results","volume":"75","author":"Valencia","year":"2022","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and Clarification: From the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_30","unstructured":"(2022, February 14). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"key":"ref_31","unstructured":"(2022, January 24). R: The R Project for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2217\/fon-2020-0573","article-title":"POLARIS: A Prospective, Multicenter, Noninterventional Study Assessing Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer","volume":"16","author":"Tripathy","year":"2020","journal-title":"Future Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Parulekar, W.R., Joy, A.A., Gelmon, K., Mates, M., Desbiens, C., Clemons, M., Taylor, S., Lemieux, J., Bartlett, J., and Whelan, T. (2019). Abstract PD1-10: Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced\/Metastatic Breast Cancer: CCTG MA38 (NCT02630693). Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-PD1-10"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, J., Luo, J., Ademuyiwa, F., Suresh, R., Rigden, C., Reardon, T., Weilbaecher, K., Frith, A., Roshal, A., and Tandra, P. (2020). Abstract P1-19-13: A Phase II Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib (Palbo) in Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC): Alt Dose Palbo. Cancer Res., 80.","DOI":"10.1158\/1538-7445.SABCS19-P1-19-13"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:33:29Z","timestamp":1760135609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/3\/145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["curroncol29030145"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29030145","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]}}}